US 12,281,359 B2
Variants of TNFSF15 and DCR3 associated with Crohn's disease
Dermot P. McGovern, Los Angeles, CA (US)
Assigned to CEDARS-SINAI MEDICAL CENTER, Los Angeles, CA (US)
Filed by CEDARS-SINAI MEDICAL CENTER, Los Angeles, CA (US)
Filed on Aug. 2, 2021, as Appl. No. 17/392,098.
Application 17/392,098 is a division of application No. 15/946,632, filed on Apr. 5, 2018, abandoned.
Application 15/946,632 is a continuation of application No. 14/890,712, abandoned, previously published as PCT/US2014/038468, filed on May 16, 2014.
Claims priority of provisional application 61/824,932, filed on May 17, 2013.
Prior Publication US 2021/0371931 A1, Dec. 2, 2021
Int. Cl. C12Q 1/68 (2018.01); C12Q 1/6883 (2018.01)
CPC C12Q 1/6883 (2013.01) [C12Q 2600/112 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/172 (2013.01)] 5 Claims
 
1. A method of treating an inflammatory bowel disease (IBD) in a subject in need thereof, the method comprising administering to the subject an anti-tumor necrosis factor-like cytokine 1A (anti-TL1A) antibody, provided that the subject comprises a polymorphism in TNFSF15 at the position “N” within SEQ ID NO: 3, SEQ ID NO: 2, SEQ ID NO: 4, or a combination thereof, wherein the polymorphism within SEQ ID NO: 3is a “G” allele; the polymorphism within SEQ ID NO: 2 is an “A” allele; and the polymorphism within SEQ ID NO: 4 is a “T” allele.